Vedolizumab
- PDF / 169,153 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 49 Downloads / 141 Views
1 S
Lack of efficacy: 2 case reports In a case series of 15 patients, who received faecal microbiota transplantation [FMT] between June 2017 and January 2020, 2 patients [ages and sexes not stated] were described, who exhibited lack of efficacy during treatment with vedolizumab for colitis. The patients, who were receiving unspecified immune checkpoint inhibitor for unspecified cancer, developed immune checkpoint inhibitor induced-colitis. Thus, they received treatment with vedolizumab [route and dosage not stated] for colitis. However, vedolizumab failed to treat the colitis. Thus, they underwent FMT. The patients had persistent symptoms of colitis. Thus, one patient was admitted and underwent colectomy, while the other patient was transferred to hospice care. Wang Y, et al. Fecal microbiota transplantation (FMT) for immune checkpoint inhibitor induced-colitis (IMC) refractory to immunosuppressive therapy. Journal of Clinical 803503322 Oncology 38 (Suppl.): abstr. 3067, No. 15, 25 May 2020. Available from: URL: http://doi.org/10.1200/JCO.2020.38.15_suppl.3067 [abstract]
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
